[stock_market_widget type=”card” template=”basic2″ assets=”INCR” realtime=”true” api=”yahoo-finance”]
A stock exchange is not just a place where shares change hands. It is also a club with rules, and one of the plainest rules on the Nasdaq Stock Market is that a company’s shares should trade for at least $1.00. When a share price drifts below that line and stays there, the exchange takes notice, and the company must lift the price back up or risk being asked to leave.
One of the most common tools for this job is the reverse stock split, sometimes called a rollback. A company reduces the number of shares in circulation and raises the price of each remaining share by the same proportion. If a business trades at $0.40 and carries out a reverse split at a ratio of one new share for every five old ones, the share count falls to a fifth of its former size and the price climbs to roughly $2.00. Nothing about the underlying company changes. An investor’s holding is worth the same on paper, since fewer shares are each worth more.
The reason companies bother is that a Nasdaq listing carries real weight. It brings visibility, easier access to capital, and a level of trust that many funds and index products require before they will hold a stock. A move to the over the counter market usually means thinner trading, wider price gaps, and a harder time raising money. So when the minimum bid rule is breached, a reverse split becomes less a matter of vanity and more a matter of keeping the doors open. [Nasdaq Listing Rules]
That is the situation now facing a medical cannabis producer based in Herzliya, Israel. InterCure Ltd. (NASDAQ: INCR), which operates through its Canndoc subsidiary and also trades in Tel Aviv, received a written notice from Nasdaq on February 25, 2026. Its ordinary shares had closed below $1.00 for 30 straight business days, breaking the exchange’s minimum bid price rule. The company was handed a window of 180 days, ending August 24, 2026, to bring the price back above a dollar for at least 10 consecutive trading days. [Nasdaq Deficiency Notice]
Rather than wait and hope the market lifted the price on its own, InterCure asked its shareholders to act. At an extraordinary general meeting held on August 12, 2026, investors approved a 1-for-5 reverse split, turning every five existing shares into one new share. The consolidated shares are set to begin trading on a split-adjusted basis when the market opens on August 24, 2026, the same day the compliance deadline arrives. In practical terms, a share worth around $0.40 before the change would open near $2.00, comfortably above the one dollar threshold. [Reverse Split Filing]
It is worth being clear about what this does and does not fix. A reverse split repairs the share price, not the business behind it. Revenue, debt, and demand for the company’s products are untouched by the reshuffling of share math. Investors tend to read these moves with caution, because a company that needs one has usually seen its stock fall a long way. Some reverse splits are followed by fresh declines when the underlying problems persist, while others hold as the business steadies. The action itself is neutral, and what matters is what happens next.
For the wider group of small companies in the cannabis sector, InterCure’s step is a familiar sign of the pressure many of them face. Cannabis stocks have had a rough stretch, and several names have drifted toward the same sub one dollar territory that triggers exchange warnings. When a recognized operator that cultivates and distributes pharmaceutical grade products across Israel, Europe, and other regulated markets has to consolidate its shares to stay listed, it says something about how far sentiment has cooled. [Company Overview]
None of this settles the larger question of whether InterCure can hold its ground once the split takes effect. The consolidation clears the immediate hurdle and keeps the company listed past its deadline, but the price still has to stay above a dollar on its own merits in the weeks ahead. Anyone watching the small end of the cannabis market will see in the coming months whether this was a lasting repair or a pause before the next test.
